Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial

IMPORTANCE: Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is unknown whether dual blockade can potentiate antitumor activity without compromising safety in patients with recurrent or metastati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA Oncol
Hauptverfasser: Siu, Lillian L., Even, Caroline, Mesía, Ricard, Remenar, Eva, Daste, Amaury, Delord, Jean-Pierre, Krauss, Jürgen, Saba, Nabil F., Nabell, Lisle, Ready, Neal E., Braña, Irene, Kotecki, Nuria, Zandberg, Dan P., Gilbert, Jill, Mehanna, Hisham, Bonomi, Marcelo, Jarkowski, Anthony, Melillo, Giovanni, Armstrong, Jon M., Wildsmith, Sophie, Fayette, Jérôme
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Medical Association 2018
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439564/
https://ncbi.nlm.nih.gov/pubmed/30383184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4628
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge